Levetiracetam Altan

Levetiracetam, the active ingredient in Levetiracetam Altan, is an anticonvulsant presented as an intravenous solution for intravenous use, marketed in the European Union. It is employed to treat partial onset seizures, generalized tonic‑clonic seizures and myoclonic seizures in patients requiring rapid seizure control.

GNH USA supplies Levetiracetam Altan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with a focus on reliable quality and regulatory compliance for critical care settings and timely delivery.

Levetiracetam is an antiepileptic agent used to manage seizure disorders.

Partial onset seizures: reduces frequency and severity of focal seizures. Generalized tonic‑clonic seizures: helps control convulsive episodes in patients with generalized epilepsy. Myoclonic seizures: decreases sudden muscle jerks associated with myoclonic epilepsy.

Levetiracetam may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness: sensation of lightheadedness or unsteadiness. - Fatigue: feeling unusually tired or weak. - Headache: mild to moderate head pain. - Irritability: mood changes or increased agitation. - Nausea: upset stomach or feeling sick. - Somnolence: increased sleepiness.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or anaphylaxis. - Mood or behavior changes: depression, suicidal thoughts, or aggression. - Blood abnormalities: thrombocytopenia or leukopenia. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Seizure worsening: increased frequency despite therapy.

When using Levetiracetam, clinicians should consider several precautionary measures to ensure safe administration. - Renal function: adjust dosing in patients with impaired kidney function. - Pregnancy: use only if benefit outweighs risk; category B. - Concomitant CNS depressants: monitor for additive sedation. - Psychiatric history: observe for mood alterations or suicidal ideation. - Drug interactions: review concurrent antiepileptic and enzyme‑inducing agents. - Store at ambient temperature: keep in original container, protect from moisture and light.

Levetiracetam can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels. - Phenytoin: may decrease levetiracetam effectiveness. - Phenobarbital: can lower levetiracetam concentrations.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase risk of adverse CNS effects. - Opioids: potential for enhanced sedation or respiratory depression. - Alcohol: may potentiate dizziness and drowsiness.